NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues were down 7 percentdue to currency headwinds.

The Hercules, California-based life science research products and clinical diagnostics firm reported revenues of $472.8 million for the quarter ended March 31, down from $509.3 million in Q1 2014 and also falling short of the consensus analyst estimate of $474.6 million.

On a currency-neutral basis, quarterly revenues increased about 1 percent compared to the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.